Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 170 articles:
HTML format

Single Articles

    February 2024
  1. CARPIANO RM, Callahan T, Elharake JA, Hotez P, et al
    Vaccination and the defence of democracy - Authors' reply.
    Lancet. 2024;403:529-530.

    Vaccination and the defence of democracy.
    Lancet. 2024;403:529.

  3. DOPPEN M, Kearns C, Hills T, Weatherall M, et al
    Intramuscular vaccination needle length: a call to arms.
    Lancet. 2024;403:528-529.

  4. NNAJI CA, Amaechi UA, Wiysonge CS
    R21/Matrix-M vaccine: optimising supply, maximising impact.
    Lancet. 2024;403:525.

    Malaria vaccines: a test for global health.
    Lancet. 2024;403:503.

    Routine malaria vaccinations begin.
    Lancet. 2024;403:423.

  7. MOORTHY V, Hamel MJ, Smith PG
    Malaria vaccines for children: and now there are two.
    Lancet. 2024 Feb 1:S0140-6736(23)02743-5. doi: 10.1016/S0140-6736(23)02743.

  8. DATOO MS, Dicko A, Tinto H, Ouedraogo JB, et al
    Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
    Lancet. 2024 Feb 1:S0140-6736(23)02511-4. doi: 10.1016/S0140-6736(23)02511.
    PubMed     Abstract available

    January 2024
  9. PATEL PD, Liang Y, Meiring JE, Chasweka N, et al
    Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.
    Lancet. 2024 Jan 25:S0140-6736(23)02031-7. doi: 10.1016/S0140-6736(23)02031.
    PubMed     Abstract available

  10. TADESSE BT, Cardona RSB, Marks F
    Long-term protection conferred by typhoid conjugate vaccines: a step towards typhoid elimination?
    Lancet. 2024 Jan 25:S0140-6736(23)02350-4. doi: 10.1016/S0140-6736(23)02350.

  11. TERAI M, Sato T
    Individualised neoantigen cancer vaccine therapy.
    Lancet. 2024 Jan 18:S0140-6736(23)02463-7. doi: 10.1016/S0140-6736(23)02463.

  12. ALVES L
    Brazil to start widespread dengue vaccinations.
    Lancet. 2024;403:133.

  13. GULLIFORD MC, Steves CJ
    Access to COVID-19 vaccination and COVID-19-related hospital admissions and mortality.
    Lancet. 2024 Jan 12:S0140-6736(23)02622-3. doi: 10.1016/S0140-6736(23)02622.

  14. Undervaccination and severe COVID-19 outcomes: meta-analysis of national cohort studies in England, Northern Ireland, Scotland, and Wales.
    Lancet. 2024 Jan 12:S0140-6736(23)02467-4. doi: 10.1016/S0140-6736(23)02467.
    PubMed     Abstract available

    December 2023
  15. THUMBI SM, Blumberg L, le Roux K, Salahuddin N, et al
    A call to accelerate an end to human rabies deaths.
    Lancet. 2023;400:2261-2264.

  16. KARIM SSA, Sikazwe I
    Building on Pasteur's legacy: producing vaccines in Africa.
    Lancet. 2023;400:2164-2166.

    November 2023
  17. KANG G
    Success from the South: the rotavirus vaccine story and its lessons.
    Lancet. 2023 Nov 28:S0140-6736(23)02520-5. doi: 10.1016/S0140-6736(23)02520.

    Nigeria targets almost 8 million girls with HPV vaccine.
    Lancet. 2023;402:1612.

  19. DU Z, Wang L, Bai Y, Pei Y, et al
    Mitigation of respiratory syncytial virus epidemics by RSVpreF vaccines after the COVID-19 pandemic in the UK: a modelling study.
    Lancet. 2023;402 Suppl 1:S39.
    PubMed     Abstract available

    October 2023
  20. MEMISH ZA, Blumberg L, Al-Maani AS, Baru R, et al
    Moving cholera vaccines ahead of the epidemic curve.
    Lancet. 2023 Oct 17:S0140-6736(23)02244-4. doi: 10.1016/S0140-6736(23)02244.

    Malaria community welcomes WHO vaccine approval.
    Lancet. 2023;402:1316.

    September 2023
  22. YANG C, Lapp L, Tebbutt SJ
    Overcoming COVID-19 vaccine hesitancy hurdles.
    Lancet. 2023;402:1129-1130.

  23. AARS OK, Schwalbe N
    Bold moves for vaccine manufacturing equity.
    Lancet. 2023;402:771-772.

    August 2023
  24. DAI L, Duan H, Liu X, Zhou H, et al
    Omicron neutralisation: RBD-dimer booster versus BF.7 and BA.5.2 breakthrough infection.
    Lancet. 2023;402:687-689.

  25. SINHA P, Mehta S
    Food: the tuberculosis vaccine we already have.
    Lancet. 2023 Aug 8:S0140-6736(23)01321-1. doi: 10.1016/S0140-6736(23)01321.

    July 2023
  26. AGUS DB, Nguyen A, Bell J
    Successful adult vaccine drives must centre disability inclusion - Authors' reply.
    Lancet. 2023;402:370.

  27. ROTENBERG S, Downer M
    Successful adult vaccine drives must centre disability inclusion.
    Lancet. 2023;402:369-370.

  28. ZHOU J, Zhang Y, Mo K, Newbert H, et al
    mRNA vaccines do not stop with COVID-19.
    Lancet. 2023 Jul 27:S0140-6736(23)01514-3. doi: 10.1016/S0140-6736(23)01514.

  29. SAIED AA
    Building Africa's first mRNA vaccine facility.
    Lancet. 2023;402:287-288.

  30. DEVI S
    12 countries to get first doses of malaria vaccine.
    Lancet. 2023;402:172.

    June 2023
  31. SCHNEIDER M, Narciso-Abraham M, Hadl S, McMahon R, et al
    Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jun 12:S0140-6736(23)00641-4. doi: 10.1016/S0140-6736(23)00641.
    PubMed     Abstract available

    Live-attenuated Chikungunya vaccine: a possible new era.
    Lancet. 2023 Jun 12:S0140-6736(23)01170-4. doi: 10.1016/S0140-6736(23)01170.

    May 2023
  33. MFINANGA SG, Gatei W, Tinuga F, Mwengee WMP, et al
    Tanzania's COVID-19 vaccination strategy: lessons, learning, and execution.
    Lancet. 2023;401:1649.

    Gavi unveils malaria vaccine plans.
    Lancet. 2023;401:1485.

    April 2023
    Why vaccinations should be a top priority in earthquake relief efforts.
    Lancet. 2023;401:1263-1264.

    March 2023
    Finding a safe and effective vaccine for the Lassa virus.
    Lancet. 2023 Mar 16:S0140-6736(23)00093-4. doi: 10.1016/S0140-6736(23)00093.

  37. TSCHISMAROV R, Van Damme P, Germain C, De Coster I, et al
    Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial.
    Lancet. 2023 Mar 16:S0140-6736(23)00048-X. doi: 10.1016/S0140-6736(23)00048.
    PubMed     Abstract available

  38. KEECH C, Miller VE, Rizzardi B, Hoyle C, et al
    Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial.
    Lancet. 2023;401:843-855.
    PubMed     Abstract available

  39. EDWARDS KM, Decker MD
    An alternative route to pertussis protection?
    Lancet. 2023;401:800-801.

    Effect of a nationwide intervention of electronic letters with behavioural nudges on influenza vaccination in older adults in Denmark.
    Lancet. 2023 Mar 3:S0140-6736(23)00453-1. doi: 10.1016/S0140-6736(23)00453.

  41. JOHANSEN ND, Vaduganathan M, Bhatt AS, Lee SG, et al
    Electronic nudges to increase influenza vaccination uptake in Denmark: a nationwide, pragmatic, registry-based, randomised implementation trial.
    Lancet. 2023 Mar 3:S0140-6736(23)00349-5. doi: 10.1016/S0140-6736(23)00349.
    PubMed     Abstract available

  42. CARPIANO RM, Callaghan T, DiResta R, Brewer NT, et al
    Confronting the evolution and expansion of anti-vaccine activism in the USA in the COVID-19 era.
    Lancet. 2023 Mar 2:S0140-6736(23)00136-8. doi: 10.1016/S0140-6736(23)00136.

    January 2023
  43. HAMER MJ, Houser KV, Hofstetter AR, Ortega-Villa AM, et al
    Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.
    Lancet. 2023;401:294-302.
    PubMed     Abstract available

  44. MANNO D
    Developing a vaccine against Marburg virus disease.
    Lancet. 2023;401:251-253.

  45. ELLINGTON S, Jatlaoui TC
    COVID-19 vaccination is effective at preventing severe illness and complications during pregnancy.
    Lancet. 2023 Jan 17:S0140-6736(22)02613-7. doi: 10.1016/S0140-6736(22)02613.

  46. VILLAR J, Soto Conti CP, Gunier RB, Ariff S, et al
    Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study.
    Lancet. 2023 Jan 17:S0140-6736(22)02467-9. doi: 10.1016/S0140-6736(22)02467.
    PubMed     Abstract available

    December 2022
  47. BUTLER CC, Hobbs FDR, Gbinigie OA, Rahman NM, et al
    Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
    Lancet. 2022 Dec 22:S0140-6736(22)02597-1. doi: 10.1016/S0140-6736(22)02597.
    PubMed     Abstract available

  48. ZAMAN K, Bandyopadhyay AS, Hoque M, Gast C, et al
    Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial.
    Lancet. 2022 Dec 7:S0140-6736(22)02397-2. doi: 10.1016/S0140-6736(22)02397.
    PubMed     Abstract available

  49. NANQUE LM, Fisker AB
    Maximising the lessons learned from trial data after emergency use listing of a novel oral polio vaccine.
    Lancet. 2022 Dec 7:S0140-6736(22)02455-2. doi: 10.1016/S0140-6736(22)02455.

    November 2022
  50. JACKSON S, Kabir Z, Comiskey C
    Impact of universal tuberculosis vaccination cessation on the epidemiology of paediatric tuberculosis cases in Ireland from 2011 to 2021.
    Lancet. 2022;400 Suppl 1:S53.
    PubMed     Abstract available

  51. ISBA R, Brennan L, Davies N, Knight J, et al
    Measles, mumps, and rubella vaccination coverage in children younger than 5 years attending a paediatric emergency department in Manchester, UK: a cross-sectional observational study.
    Lancet. 2022;400 Suppl 1:S51.
    PubMed     Abstract available

  52. BURNS R, Campos-Matos I, Harron K, Aldridge RW, et al
    COVID-19 vaccination uptake for half a million non-EU migrants and refugees in England: a linked retrospective population-based cohort study.
    Lancet. 2022;400 Suppl 1:S5.
    PubMed     Abstract available

  53. HUF SW, Woldmann L, Crespo RF, Grailey K, et al
    Implementing behavioural science informed letter interventions to increase COVID-19 vaccination uptake in uncontactable London residents: a difference-in-difference study in London, UK.
    Lancet. 2022;400 Suppl 1:S41.
    PubMed     Abstract available

    October 2022
  54. KLAPSA D, Wilton T, Zealand A, Bujaki E, et al
    Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance.
    Lancet. 2022;400:1531-1538.
    PubMed     Abstract available

  55. HILL M, Pollard AJ
    Detection of poliovirus in London highlights the value of sewage surveillance.
    Lancet. 2022;400:1491-1492.

  56. AGUS DB, Nguyen A, Sall AA, Bell J, et al
    COVID-19 and other adult vaccines can drive global disease prevention.
    Lancet. 2022 Oct 27. pii: S0140-6736(22)02084.

  57. OPEL DJ, Brewer NT, Buttenheim AM, Callaghan T, et al
    The legacy of the COVID-19 pandemic for childhood vaccination in the USA.
    Lancet. 2022 Oct 26. pii: S0140-6736(22)01693.

  58. AGRAWAL U, Bedston S, McCowan C, Oke J, et al
    Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.
    Lancet. 2022;400:1305-1320.
    PubMed     Abstract available

  59. MSELLATI P, Sow K, Desclaux A, Cottrell G, et al
    Reconsidering the COVID-19 vaccine strategy in West and Central Africa.
    Lancet. 2022;400:1304.

    September 2022
  60. HAMEED SS, Hall E, Grange Z, Sullivan C, et al
    Characterising adults in Scotland who are not vaccinated against COVID-19.
    Lancet. 2022;400:993-995.

  61. ZIEGLER T, Moen A, Zhang W, Cox NJ, et al
    Global Influenza Surveillance and Response System: 70 years of responding to the expected and preparing for the unexpected.
    Lancet. 2022;400:981-982.

    August 2022
  62. UYEKI TM, Hui DS, Zambon M, Wentworth DE, et al
    Lancet. 2022;400:693-706.
    PubMed     Abstract available

  63. HILL M, Bandyopadhyay AS, Pollard AJ
    Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use.
    Lancet. 2022 Aug 18. pii: S0140-6736(22)01582.

    July 2022
    Perilous two-tier COVID-19 global vaccine roll-out.
    Lancet. 2022 Jul 11. pii: S0140-6736(22)01284.

  65. MELLO MM, Opel DJ, Benjamin RM, Callaghan T, et al
    Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the USA.
    Lancet. 2022 Jul 8. pii: S0140-6736(22)00875.

    June 2022
  66. SACCO C, Del Manso M, Mateo-Urdiales A, Rota MC, et al
    Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
    Lancet. 2022 Jun 30. pii: S0140-6736(22)01185.
    PubMed     Abstract available

    COVID-19 vaccination for children aged 5-11 years.
    Lancet. 2022 Jun 30. pii: S0140-6736(22)01245.

  68. LI G, Cappuccini F, Marchevsky NG, Aley PK, et al
    Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Lancet. 2022;399:2212-2225.
    PubMed     Abstract available

  69. WONG HL, Hu M, Zhou CK, Lloyd PC, et al
    Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
    Lancet. 2022;399:2191-2199.
    PubMed     Abstract available

  70. PATEL M, Patel M
    Increasing children's global access to COVID-19 vaccines.
    Lancet. 2022;399:2171-2173.

  71. HUSBY A, Kober L
    COVID-19 mRNA vaccination and myocarditis or pericarditis.
    Lancet. 2022;399:2168-2169.

    May 2022
  72. SASIENI P, Castanon A
    HPV vaccination and cervical cancer screening - Authors' reply.
    Lancet. 2022;399:1940.

  73. BEWLEY S
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939.

  74. KAMAMOTO S, Murayama A, Hamaki T, Kusumi E, et al
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939-1940.

    Eliminating cholera in Haiti.
    Lancet. 2022;399:1928-1929.

  76. DZAU VJ, Balatbat CA, Offodile AC 2nd
    Closing the global vaccine equity gap: equitably distributed manufacturing.
    Lancet. 2022 May 6. pii: S0140-6736(22)00793.

    April 2022
    Africa CDC warns COVID-19 vaccine production could cease.
    Lancet. 2022;399:1683.

  78. NGUYEN-TRAN H, Messacar K
    Preventing enterovirus A71 disease: another promising vaccine for children.
    Lancet. 2022 Apr 12. pii: S0140-6736(22)00380.

  79. NGUYEN TT, Chiu CH, Lin CY, Chiu NC, et al
    Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2022 Apr 12. pii: S0140-6736(22)00313.
    PubMed     Abstract available

  80. BUCHBINDER SP, McElrath MJ, Dieffenbach C, Corey L, et al
    COVID-19 vaccination and HIV-1 acquisition - Authors' reply.
    Lancet. 2022;399:e36.

  81. LOGUNOV DY, Livermore DM, Ornelles DA, Bayer W, et al
    COVID-19 vaccination and HIV-1 acquisition.
    Lancet. 2022;399:e34-e35.

  82. MENNI C, Valdes AM, Polidori L, Antonelli M, et al
    Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.
    Lancet. 2022 Apr 7. pii: S0140-6736(22)00327.
    PubMed     Abstract available

  83. WINTER AK, Moss WJ
    Lancet. 2022;399:1336-1346.
    PubMed     Abstract available

  84. KHOBRAGADE A, Bhate S, Ramaiah V, Deshpande S, et al
    Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India.
    Lancet. 2022;399:1313-1321.
    PubMed     Abstract available

  85. BLAKNEY AK, Bekker LG
    DNA vaccines join the fight against COVID-19.
    Lancet. 2022;399:1281-1282.

    March 2022
  86. KRAUSE PR, Rees H, Figueroa JP, Swaminathan S, et al
    Booster vaccines for COVID-19 vaccine breakthrough cases? - Authors' reply.
    Lancet. 2022;399:1225.

  87. NIXON DF, Schwartz RE, Ndhlovu LC
    Booster vaccines for COVID-19 vaccine breakthrough cases?
    Lancet. 2022;399:1224.

  88. BEKKER LG, Garrett N, Goga A, Fairall L, et al
    Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study.
    Lancet. 2022;399:1141-1153.
    PubMed     Abstract available

  89. USHER AD
    CEPI launches 100-day vaccine "moonshot".
    Lancet. 2022;399:1107-1108.

  90. REARTE A, Castelli JM, Rearte R, Fuentes N, et al
    Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
    Lancet. 2022 Mar 15. pii: S0140-6736(22)00011.
    PubMed     Abstract available

  91. MILLS EJ, Reis G
    Evaluating COVID-19 vaccines in the real world.
    Lancet. 2022 Mar 15. pii: S0140-6736(22)00194.

  92. MANCA T, Baylis F, Munoz FM, Top KA, et al
    Prioritise research on vaccines for pregnant and breastfeeding women.
    Lancet. 2022;399:890-893.

  93. FALLAH MP, Reinhart E
    Apartheid logic in global health.
    Lancet. 2022;399:902-903.

  94. NUNEZ I
    Vaccine approval before phase 3 trial results: a consequence of vaccine access inequity.
    Lancet. 2022 Mar 2. pii: S0140-6736(22)00164.

    February 2022
  95. CHEMAITELLY H, Abu-Raddad LJ
    Waning effectiveness of COVID-19 vaccines.
    Lancet. 2022;399:771-773.

  96. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.
    Lancet. 2022 Feb 24. pii: S0140-6736(21)02867.
    PubMed     Abstract available

  97. BAJAJ SS, Maki L, Stanford FC
    Vaccine apartheid: global cooperation and equity.
    Lancet. 2022 Feb 23. pii: S0140-6736(22)00328.

  98. PIECHOTTA V, Harder T
    Waning of COVID-19 vaccine effectiveness: individual and public health risk.
    Lancet. 2022 Feb 21. pii: S0140-6736(22)00282.

  99. FEIKIN DR, Higdon MM, Abu-Raddad LJ, Andrews N, et al
    Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.
    Lancet. 2022 Feb 21. pii: S0140-6736(22)00152.
    PubMed     Abstract available

  100. KALAFAT E, Magee LA, von Dadelszen P, Heath P, et al
    COVID-19 booster doses in pregnancy and global vaccine equity.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00166.

  101. MADHI SA, Ihekweazu C, Rees H, Pollard AJ, et al
    Decoupling of omicron variant infections and severe COVID-19.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00109.

  102. EGGER S, Egger G
    The vaccinated propor-tion of people with COVID-19 needs context.
    Lancet. 2022;399:627.

  103. CAPLAN AL
    Stigma, vaccination, and moral accountability.
    Lancet. 2022;399:626-627.

    Ayoade Alakija: advancing equity in the COVID-19 response.
    Lancet. 2022;399:511.

  105. BURKI T
    Fresh questions over Gates Foundation governance.
    Lancet. 2022;399:508.

  106. BEYRER C
    Archbishop Desmond Tutu and the universality of health and human rights.
    Lancet. 2022;399:503-504.

  107. NORDSTROM P, Ballin M, Nordstrom A
    Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden.
    Lancet. 2022 Feb 4. pii: S0140-6736(22)00089.
    PubMed     Abstract available

  108. KARAFILLAKIS E, Van Damme P, Hendrickx G, Larson HJ, et al
    COVID-19 in Europe: new challenges for addressing vaccine hesitancy.
    Lancet. 2022 Feb 3. pii: S0140-6736(22)00150.

  109. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021.
    Lancet. 2022 Feb 1. pii: S0140-6736(22)00172.
    PubMed     Abstract available

    January 2022
  110. JAFFE S
    The next steps for US vaccine mandates.
    Lancet. 2022;399:425-426.

  111. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.
    Lancet. 2022 Jan 27. pii: S0140-6736(22)00101.
    PubMed     Abstract available

  112. HUBSCHEN JM, Gouandjika-Vasilache I, Dina J
    Lancet. 2022 Jan 27. pii: S0140-6736(21)02004.
    PubMed     Abstract available

  113. FENDLER A, Shepherd STC, Au L, Wu M, et al
    Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.
    Lancet. 2022 Jan 25. pii: S0140-6736(22)00147.

  114. LANE R
    Jamal Rifi: family doctor building bridges in the community.
    Lancet. 2022;399:353.

  115. COSTA CLEMENS SA, Weckx L, Clemens R, Almeida Mendes AV, et al
    Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00094.
    PubMed     Abstract available

  116. BRAVO L, Smolenov I, Han HH, Li P, et al
    Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
    Lancet. 2022 Jan 20. pii: S0140-6736(22)00055.
    PubMed     Abstract available

    Trimeric S protein COVID-19 vaccine needs to find its place.
    Lancet. 2022 Jan 20. pii: S0140-6736(22)00096.

  118. CARR EJ, Wu M, Harvey R, Billany RE, et al
    Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients.
    Lancet. 2022 Jan 20. pii: S0140-6736(22)00104.

  119. WU M, Wall EC, Carr EJ, Harvey R, et al
    Three-dose vaccination elicits neutralising antibodies against omicron.
    Lancet. 2022 Jan 19. pii: S0140-6736(22)00092.

  120. KUHLMANN C, Mayer CK, Claassen M, Maponga T, et al
    Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.
    Lancet. 2022 Jan 18. pii: S0140-6736(22)00090.

    December 2021
  121. KING J, Ferraz OLM, Jones A
    Mandatory COVID-19 vaccination and human rights.
    Lancet. 2021 Dec 23. pii: S0140-6736(21)02873.

  122. HALPERIN SA, Ye L, MacKinnon-Cameron D, Smith B, et al
    Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-
    Lancet. 2021 Dec 23. pii: S0140-6736(21)02753.
    PubMed     Abstract available

    Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine.
    Lancet. 2021 Dec 23. pii: S0140-6736(21)02834.

  124. LEUNG K, Wu JT
    Managing waning vaccine protection against SARS-CoV-2 variants.
    Lancet. 2021 Dec 20. pii: S0140-6736(21)02841.

  125. KATIKIREDDI SV, Cerqueira-Silva T, Vasileiou E, Robertson C, et al
    Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.
    Lancet. 2021 Dec 20. pii: S0140-6736(21)02754.
    PubMed     Abstract available

  126. PEELING RW, Heymann DL, Teo YY, Garcia PJ, et al
    Diagnostics for COVID-19: moving from pandemic response to control.
    Lancet. 2021 Dec 20. pii: S0140-6736(21)02346.
    PubMed     Abstract available

  127. MCINTYRE PB, Aggarwal R, Jani I, Jawad J, et al
    COVID-19 vaccine strategies must focus on severe disease and global equity.
    Lancet. 2021 Dec 16. pii: S0140-6736(21)02835.

  128. STUART ASV, Shaw RH, Liu X, Greenland M, et al
    Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
    Lancet. 2021 Dec 6. pii: S0140-6736(21)02718.
    PubMed     Abstract available

    Mixing mRNA, adenoviral, and spike-adjuvant vaccines for protection against COVID-19.
    Lancet. 2021 Dec 6. pii: S0140-6736(21)02757.

  130. KARIM SSA, Karim QA
    Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.
    Lancet. 2021 Dec 3. pii: S0140-6736(21)02758.

  131. MENDELSON M, Venter F, Moshabela M, Gray G, et al
    The political theatre of the UK's travel ban on South Africa.
    Lancet. 2021 Dec 3. pii: S0140-6736(21)02752.

  132. MUNRO APS, Janani L, Cornelius V, Aley PK, et al
    Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
    Lancet. 2021 Dec 2. pii: S0140-6736(21)02717.
    PubMed     Abstract available

    November 2021
  133. JAFFE S
    Legal challenges threaten Biden's COVID-19 vaccine rule.
    Lancet. 2021;398:1863-1864.

  134. BURKI T
    mRNA discoveries earn the 2021 Prince Mahidol Award.
    Lancet. 2021;398:1865.

  135. OMER SB, Benjamin RM, Brewer NT, Buttenheim AM, et al
    Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.
    Lancet. 2021 Nov 15. pii: S0140-6736(21)02507.
    PubMed     Abstract available

  136. PAVORD S, Scully M, Lester W, Makris M, et al
    Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine?
    Lancet. 2021;398:1801.

  137. BHUYAN P, Medin J, da Silva HG, Yadavalli M, et al
    Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? - Authors' reply.
    Lancet. 2021;398:1801-1802.

  138. LAZARUS R, Baos S, Cappel-Porter H, Carson-Stevens A, et al
    Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02329.
    PubMed     Abstract available

  139. ELLA R, Reddy S, Blackwelder W, Potdar V, et al
    Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02000.
    PubMed     Abstract available

  140. LI JX, Zhu FC
    Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02014.

  141. ALVES L
    Health experts welcome Brazil COVID-19 inquiry findings.
    Lancet. 2021;398:1674-1675.

  142. USHER AD
    New budget and strategy for ACT-A.
    Lancet. 2021;398:1677.

    WHO's Tedros set to be re-elected unopposed.
    Lancet. 2021;398:1676.

  144. ORTIZ JR, Neuzil KM
    The value of vaccine programme impact monitoring during the COVID-19 pandemic.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02322.

  145. MCNAMARA LA, Wiegand RE, Burke RM, Sharma AJ, et al
    Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02226.
    PubMed     Abstract available

  146. FALCARO M, Castanon A, Ndlela B, Checchi M, et al
    The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02178.
    PubMed     Abstract available

    October 2021
  147. HODGES S, Hornberger J, Kufakurinani U, Rudra S, et al
    When suspicion replaces evidence in public health.
    Lancet. 2021;398:1565-1566.

  148. BARDA N, Dagan N, Cohen C, Hernan MA, et al
    Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
    Lancet. 2021 Oct 29. pii: S0140-6736(21)02249.
    PubMed     Abstract available

  149. GRANGE Z, Buelo A, Sullivan C, Moore E, et al
    Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland.
    Lancet. 2021 Oct 28. pii: S0140-6736(21)02316.

  150. SONABEND R, Whittles LK, Imai N, Perez-Guzman PN, et al
    Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
    Lancet. 2021 Oct 27. pii: S0140-6736(21)02276.
    PubMed     Abstract available

  151. USHER AD
    Vaccine shortages prompt changes to COVAX strategy.
    Lancet. 2021;398:1474.

  152. HILLSON K, Clemens SC, Madhi SA, Voysey M, et al
    Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination.
    Lancet. 2021 Oct 21. pii: S0140-6736(21)02282.

    Cautious optimism for malaria vaccine roll-out.
    Lancet. 2021;398:1394.

  154. SAAG MS
    Developing COVID-19 vaccine policy in increments.
    Lancet. 2021;398:1382-1383.

    Malaria vaccine approval: a step change for global health.
    Lancet. 2021;398:1381.

  156. PRENDECKI M, Thomson T, Clarke CL, Martin P, et al
    Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients.
    Lancet. 2021 Oct 4. pii: S0140-6736(21)02096.

  157. TARTOF SY, Slezak JM, Fischer H, Hong V, et al
    Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.
    Lancet. 2021 Oct 4. pii: S0140-6736(21)02183.
    PubMed     Abstract available

    September 2021
    COVID-19: learning as an interdependent world.
    Lancet. 2021;398:1105.

  159. LANE R
    Gagandeep Kang: helping to shape a healthier India.
    Lancet. 2021;398:947.

  160. ALIBERTI S, Dela Cruz CS, Amati F, Sotgiu G, et al
    Community-acquired pneumonia.
    Lancet. 2021;398:906-919.
    PubMed     Abstract available

  161. FLAXMAN A, Marchevsky NG, Jenkin D, Aboagye J, et al
    Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
    Lancet. 2021 Sep 1. pii: S0140-6736(21)01699.
    PubMed     Abstract available

    August 2021
  162. USHER AD
    Health leaders criticise limited ACT-A review.
    Lancet. 2021;398:650-651.

    July 2021
  163. KICKBUSCH I, Leung GM, Shattock RJ
    Learning from crisis: building resilient systems to combat future pandemics.
    Lancet. 2021;398:e2-e6.

    June 2021
    Colombians protest over inequities and health care.
    Lancet. 2021;397:2454.

  165. USHER AD
    A beautiful idea: how COVAX has fallen short.
    Lancet. 2021;397:2322-2325.

  166. USHER AD
    ACT Accelerator strains donors' aid budgets.
    Lancet. 2021;397:2137.

    May 2021
  167. SAXENA SG, Godfrey T
    Catalysing needed change for health systems in the USA.
    Lancet. 2021;397:1705-1706.

  168. REINHART E, Dawes D, Maybank A
    Structural medicine: towards an economy of care.
    Lancet. 2021;397:1691-1693.

    March 2021
    Myanmar's democracy and health on life support.
    Lancet. 2021;397:1035.

  170. DEVI S
    Health in Syria: a decade of conflict.
    Lancet. 2021;397:955-956.

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.